Candriam SCA’s TRACON Pharmaceuticals TCON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
– Sell
-715
Closed -$293K – 857
2018
Q3
$293K Hold
715
– – ﹤0.01% 756
2018
Q2
$386K Hold
715
– – 0.01% 723
2018
Q1
$329K Hold
715
– – 0.01% 715
2017
Q4
$479K Hold
715
– – 0.01% 686
2017
Q3
$450K Buy
+715
New +$372K 0.01% 677
2017
Q2
– Sell
-715
Closed -$536K – 719
2017
Q1
$536K Hold
715
– – 0.01% 644
2016
Q4
$701K Hold
715
– – 0.02% 572
2016
Q3
$967K Hold
715
– – 0.02% 502
2016
Q2
$626K Sell
715
-100
-12% -$132K 0.02% 528
2016
Q1
$1.13M Sell
815
-85
-9% -$121K 0.03% 409
2015
Q4
$1.66M Buy
900
+223
+33% +$446K 0.04% 326
2015
Q3
$1.32M Buy
677
+52
+8% +$122K 0.03% 399
2015
Q2
$1.42M Hold
625
– – 0.03% 402
2015
Q1
$1.76M Buy
+625
New +$1.64M 0.04% 408

Other funds holding TCON

Candriam SCA's TCON Position: Q4 2018 in Review

Candriam SCA sold out of TRACON Pharmaceuticals (TCON) in Q4 2018, closing a stake of 715 shares — an estimated $293K sold.

Candriam SCA first reported a position in TCON in Q1 2015 and held it in 14 quarters. The position peaked at $1.76M in Q1 2015. 27 funds tracked by Wall St. Rank hold TCON as of Q4 2018.

  • Candriam SCA reported no remaining TRACON Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Candriam SCA sold 715 TRACON Pharmaceuticals shares in Q4 2018, an estimated $293K.
  • Candriam SCA first reported a position in TRACON Pharmaceuticals in Q1 2015 and held it in 14 quarters.
  • Candriam SCA's TRACON Pharmaceuticals position peaked at $1.76M in Q1 2015.
  • 27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals as of Q4 2018.

Based on Candriam SCA's 13F filing for Q4 2018, filed 14 Feb 2019.